Immunogenicity assessment of antibody therapeutics

Recombinant Antibodies for Immunotherapy

Volumn , Issue , 2009, Pages 20-42

  Stas, Philippe ^a   Pletinckx, Jurgen ^a   Gansemans, Yannick ^a   Lasters, Ignace ^a  

^a Algonomics   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885619169     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596773.005     Document Type: Chapter

References (117)

1. Anthony DD and Lehmann PV. T-cell epitope mapping using the ELISPOT approach. Methods 2003; 29: 260-269.
2. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, and Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262: 1448-1451.
3. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, and Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
4. Bearden CM, Book BK, Sidner RA, and Pescovitz MD. Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing. J Immunol Methods 2005; 300: 192-199.
5. Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, and Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27: 269-274.
6. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, and Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184: 350-354.
7. Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, et al. Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9:3961s-3972s.
8. Borrás-Cuesta F, Golvano J, García-Granero M, Sarobe P, Riezu-Boj J, Huarte E, and Lasarte J. Specific and general HLA-DR binding motifs: comparison of algorithms. Hum Immunol 2000; 61: 266-278.
9. Bowen JD, Petersdorf SH, Richards TL, Maravilla KR, Dale DC, Price TH, St John TP, and Yu AS. Phase I study of a humanised anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 1998; 64: 339-346.
10. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190.
11. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J, et al. A humanised non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99:2712-2719.
12. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, and Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346(7):469-475.
13. Castellino F, Zhong G, and Germain RN. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum Immunol 1997; 54: 159-169.
14. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, and Strominger JL. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992; 358: 764-768.
15. Choy EHS, Schantz A, Pitzalis C, Kingsley GH, and Panayi GS. The pharmacokinetics and human anti-mouse antibody response in rheumatoid arthritis patients treated with a chimeric anti-CD4 monoclonal antibody. Br J Rheumatol 1998; 37: 801-802.
16. Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, Heider KH, Stehle G, Snow GB, and van Dongen GA. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanised monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003; 52: 576-582.
17. Davenport MP, Smith KJ, Barouch D, Reid SW, Bodnar WM, Willis AC, Hunt DF, and Hill AV. HLA Class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. J Exp Med 1997; 185: 367-371.
18. Davies MN, Sansom CE, Beazley C, and Moss DS. A novel predictive technique for the MHC class II peptide-binding interaction. Mol Med 2003; 9: 220-225.
19. Davis MM and Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395-402.
20. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, and Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
21. Desmet J, Meersseman G, Boutonnet N, Pletinckx J, De Clercq K, Debulpaep M, Braeckman T, and Lasters I. Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation. Proteins 2005; 58: 53-69.
22. Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, and Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Resp Crit Care Medicine, 2005; 170, 583-593.
23. European Agency for the Evaluation of Medicinal Products (EMEA) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006, draft 2007.
24. Eng JK, McCormack AL, and Yates JR III. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994; 5: 976-989.
25. Falk K, Roetzschke O, Stefanovic S, Jung G, and Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-296.
26. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, et al. Treatment of ulcerative colitis with a humanised antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-2507.
27. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24-32.
28. Goldstein G, Fuccello AJ, Norman DJ, Shield CF 3rd, Colvin RB, and Cosimi AB. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986; 42: 507-511.
29. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, and Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
30. Gulukota K, Sidney J, Sette A, and DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 1997; 267: 1258-1267.
31. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, and Cheresh DA. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6: 3056-3061.
32. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, and Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994; 180: 2353-2358.
33. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13: 16-22.
34. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
35. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, and Neithammer D. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A:261-267.
36. Harding F. CD4+ T cell epitope identification: applications to allergy. Clin Exp Allergy 2003; 33: 557-565.
37. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355; 1233-1243.
38. Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Appella E, Grey HM, and Sette A. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992; 256: 1817-1820.
39. Hwang W and Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3-10.
40. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St Clair EW, Schnitzer TJ, and Johnston JM. CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J Rheumatol 1996a; 35: 231-240.
41. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, and Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-752.
42. Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, and Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 1996b; 106: 427-433.
43. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, and Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372-380.
44. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-3928.
45. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, and Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411.
46. Koren, E. From characterization of antibodies to prediction of immunogenicity. Dev Biol 2002; 109: 87-95.
47. Kovarik J, Wolf P, Cisterne JM, Mourad G, Lebranchu Y, Lang P, Bourbigot B, Cantarovich D, Girault D, Gerbeau C, Schmidt AG, and Soulillou JP. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701-1705.
48. Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, and Ceriani RL. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 1998; 4: 1679-1688.
49. Kropshofer H, Hämmerling GJ, and Vogt AB. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules. Immunol Rev 1999; 172: 267-278.
50. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-1602.
51. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, and Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
52. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-1563.
53. Mamitsuka H. Predicting peptides that bind to MHC molecules using supervised learning of Hidden Markov Models. Proteins 1998; 33: 460-474.
54. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, and Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19: 851-856.
55. Martin W, Sbai H, and De Groot AS. Bioinformatics tools for identifying class I-restricted epitopes. Methods, March 2003, 29(3): 289-298.
56. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-831.
57. McFarland BJ and Beeson C. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med Res Rev 2002; 22: 168-203.
58. McIntyre JA, Kincade M, and Higgins NG. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. Transplantation 1996; 61: 1465-1469.
59. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, and Gulliver W. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38.
60. Milik M, Sauer D, Brunmark AP, Yuan L, Vitiello A, Jackson MR, Peterson PA, Skolnick J, and Glass CA. Application of an artificial neural network to predict specific class I MHC binding peptide sequences. Nat Biotechnol 1998; 16: 753-756.
61. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289:1-16.
62. Østensen M, Sicher P, Forger F, and Villiger PM. Activation markers of peripheral blood mononuclear cells in late pregnancy and after delivery: a pilot study. Ann Rheum Dis 2005; 64: 318-320.
63. Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, and Efalizumab Study Group. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54:S164-S170.
64. Patton A, Mullenix MC, Swanson SJ, and Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304: 189-195.
65. Peters B and Sette A: Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 6:132.
66. Peters B, Tong W, Sidney J, Sette A, and Weng Z. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics 2003; 19: 1765-1772.
67. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, and Bootsma H. Rituximab treatment in patients with primary Sjögren's syndrome: an openlabel phase II study. Arthritis Rheum 2005 52:2740-2750.
68. Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655-661.
69. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
70. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
71. Reche PA, Glutting JP, Zhang H, and Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004; 56: 405-419.
72. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005; 10: 79-93.
73. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, and Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanised monoclonal antibody A33. Cancer Res 2001; 61: 6851-6859.
74. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8: E501-E507.
75. Rosenberg AS and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 1 - considering consequences of the immune response to a protein. Biopharm Int 2004a; 17: 22-26.
76. Rosenberg AS and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 2 - considering host-specific and product-specific factors impacting immunogenicity. Biopharm Int 2004b; 17: 34-42.
77. Rosenberg AS and Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products - Part 3 - effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm Int 2005; 18: 32-36.
78. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, and Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353:622-627.
79. Rudolf MP, Man S, Melief CJM, Sette A, and Kast WM. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001; 7: 788s-795s.
80. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330-1338.
81. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, and PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228-238.
82. Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, and Hoermann K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007; 30: 927-935.
83. Sawada T, Nishihara T, Yamamoto A, Teraoka H, Yamashita Y, Okamura T, Ochi H, Ho JJ, Kim YS, and Hirakawa K. Preoperative clinical radioimmunodetection of pancreatic cancer by 111 In-labeled chimeric monoclonal antibody Nd2. Jpn J Cancer Res 1999; 90: 1179-1186.
84. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807-818.
85. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, and PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239-250.
86. Schroeder TJ, First MR, Hurtubise PE, Marmer DJ, Martin DM, Mansour ME, and Melvin DB. Immunologic monitoring with Orthoclone OKT3 therapy. J Heart Transplant 1989; 8: 371-380.
87. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005; 11:4810-4817.
88. Segal MR, Cummings MP, and Hubbard AE. Relating amino acid sequence to phenotype: analysis of peptide-binding data. Biometrics 2001; 57: 632-642.
89. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C, Colon SM, and Grey HM. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci USA 1989; 86: 3296-3300.
90. Sidney J, Southwood S, Oseroff C, del Guerico MF, Grey HM, and Sette A. Measurement of MHC/peptide interactions by gel filtration. In: Current Protocols in Immunology, Wiley, New York (1998):18.13.1-18.13.19.
91. Singh H and Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001; 17: 1236-1237.
92. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, and Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160: 3363-3373.
93. Starr TK, Jameson SC, and Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003; 21: 139-176.
94. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, and Pradier O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8: R129.
95. Stickler M, Chin R, Faravashi N, Gebel W, Razo OJ, Rochanayon N, Power S, Valdes AM, Holmes S, and Harding FA. Human population-based identification of CD4+ T-cell peptide epitope determinants. J Immunol Methods 2003; 281: 95-108.
96. Stickler M, Rochanayon N, Razo OJ, Mucha J, Gebel W, Faravashi N, Chin R, Holmes S, and Harding FA. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol Sci 2004; 77: 280-289.
97. Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 2000; 6:3046- 3055.
98. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17:555-561.
99. Tangri S, Mothé BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, Zinckgraf J, Bilsel P, Newman M, Chesnut R, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 2005; 174:3187-3196.
100. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, and Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
101. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104:870-875.
102. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 2006; 102:531-537.
103. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12: 6064-6072.
104. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003; 21:211-222.
105. Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT, and Levine A. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosisinducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 1999; 5: 3906-3913.
106. Van Walle I, Gansemans Y, Parren PW, Stas P, and Lasters I. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007; 7: 405-418.
107. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63:508-516.
108. van Zanten-Przybysz I, Molthoff C, Gebbinck JK, von Mensdorff-Pouilly S, Verstraeten R, Kenemans P, and Verheijen R. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin Oncol 2002; 128: 484-492.
109. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, and Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-1231.
110. Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, and Light S. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33-38.
111. Warmerdam PA, Vanderlick K, Vandervoort P, De Smedt H, Plaisance S, De Maeyer M, and Collen D. Staphylokinase-specific cell-mediated immunity in humans. J Immunol 2002; 168: 155-161.
112. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995; 38:1589-1594.
113. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, and Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
114. Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, and Kemeny NE. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 2003a; 9: 1338-1346.
115. Welt S, Ritter G, Williams C Jr, Cohen LS, Jungbluth A, Richards EA, Old LJ, and Kemeny NE. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003b; 9: 1347-1353.
116. Zhao Y, Pinilla C, Valmori D, Martin R, and Simon R. Application of support vector machines for T-cell epitopes prediction. Bioinformatics 2003; 19: 1978-1984.
117. Zhou LJ and Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.